Cargando…

Assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression

BACKGROUND: Autoantibodies are critical elements in RA pathogenesis and clinical assessment. The anti-malondialdehyde-acetaldehyde (anti-MAA) antibodies are potentially useful because of their claimed high sensitivity for all RA patients, including those lacking RF and anti-CCP antibodies. Therefore...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez-Martinez, Lorena, García-Moreno, Cristina, Perez-Pampin, Eva, Gómara, María J., Sarmiento-Monroy, Juan C., Lopez-Golán, Yolanda, Gómez-Puerta, José A., Mera-Varela, Antonio, Conde, Carmen, Sanmartí, Raimon, Haro, Isabel, González, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552211/
https://www.ncbi.nlm.nih.gov/pubmed/37798800
http://dx.doi.org/10.1186/s13075-023-03180-x
_version_ 1785115911696416768
author Rodriguez-Martinez, Lorena
García-Moreno, Cristina
Perez-Pampin, Eva
Gómara, María J.
Sarmiento-Monroy, Juan C.
Lopez-Golán, Yolanda
Gómez-Puerta, José A.
Mera-Varela, Antonio
Conde, Carmen
Sanmartí, Raimon
Haro, Isabel
González, Antonio
author_facet Rodriguez-Martinez, Lorena
García-Moreno, Cristina
Perez-Pampin, Eva
Gómara, María J.
Sarmiento-Monroy, Juan C.
Lopez-Golán, Yolanda
Gómez-Puerta, José A.
Mera-Varela, Antonio
Conde, Carmen
Sanmartí, Raimon
Haro, Isabel
González, Antonio
author_sort Rodriguez-Martinez, Lorena
collection PubMed
description BACKGROUND: Autoantibodies are critical elements in RA pathogenesis and clinical assessment. The anti-malondialdehyde-acetaldehyde (anti-MAA) antibodies are potentially useful because of their claimed high sensitivity for all RA patients, including those lacking RF and anti-CCP antibodies. Therefore, we aimed to replicate these findings. METHODS: We independently attempted replication in Santiago and Barcelona using sera from 517 and 178 RA patients and 272 and 120 healthy controls, respectively. ELISA protocols for anti-MAA antibodies included five antigens (human serum albumin in three formulations, fibrinogen, and a synthetic peptide) and assays for the IgG, IgM, and IgA isotypes. We integrated our results with information found by searching the Web of Science for reports of anti-MAA antibodies in RA. The available patients (4989 in 11 sets) were included in a meta-analysis aimed at heterogeneity between studies. Factors accounting for heterogeneity were assessed with meta-regression. RESULTS: The sensitivity of anti-MAA antibodies in our RA patients was low, even in seropositive patients, with the percentage of positives below 23% for all ELISA conditions. Our results and bibliographic research showed IgG anti-MAA positive patients ranging from 6 to 92%. The extreme between-studies heterogeneity could be explained (up to 43%) in univariate analysis by sex, African ethnicity, the site of study, or recruitment from the military. The best model, including African ancestry and smoking, explained a high heterogeneity fraction (74%). CONCLUSION: Anti-MAA antibody sensitivity is extremely variable between RA patient collections. A substantial fraction of this variability cannot be attributed to ELISA protocols. On the contrary, heterogeneity is determined by complex factors that include African ethnicity, smoking, and sex. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-023-03180-x.
format Online
Article
Text
id pubmed-10552211
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105522112023-10-06 Assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression Rodriguez-Martinez, Lorena García-Moreno, Cristina Perez-Pampin, Eva Gómara, María J. Sarmiento-Monroy, Juan C. Lopez-Golán, Yolanda Gómez-Puerta, José A. Mera-Varela, Antonio Conde, Carmen Sanmartí, Raimon Haro, Isabel González, Antonio Arthritis Res Ther Research BACKGROUND: Autoantibodies are critical elements in RA pathogenesis and clinical assessment. The anti-malondialdehyde-acetaldehyde (anti-MAA) antibodies are potentially useful because of their claimed high sensitivity for all RA patients, including those lacking RF and anti-CCP antibodies. Therefore, we aimed to replicate these findings. METHODS: We independently attempted replication in Santiago and Barcelona using sera from 517 and 178 RA patients and 272 and 120 healthy controls, respectively. ELISA protocols for anti-MAA antibodies included five antigens (human serum albumin in three formulations, fibrinogen, and a synthetic peptide) and assays for the IgG, IgM, and IgA isotypes. We integrated our results with information found by searching the Web of Science for reports of anti-MAA antibodies in RA. The available patients (4989 in 11 sets) were included in a meta-analysis aimed at heterogeneity between studies. Factors accounting for heterogeneity were assessed with meta-regression. RESULTS: The sensitivity of anti-MAA antibodies in our RA patients was low, even in seropositive patients, with the percentage of positives below 23% for all ELISA conditions. Our results and bibliographic research showed IgG anti-MAA positive patients ranging from 6 to 92%. The extreme between-studies heterogeneity could be explained (up to 43%) in univariate analysis by sex, African ethnicity, the site of study, or recruitment from the military. The best model, including African ancestry and smoking, explained a high heterogeneity fraction (74%). CONCLUSION: Anti-MAA antibody sensitivity is extremely variable between RA patient collections. A substantial fraction of this variability cannot be attributed to ELISA protocols. On the contrary, heterogeneity is determined by complex factors that include African ethnicity, smoking, and sex. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-023-03180-x. BioMed Central 2023-10-05 2023 /pmc/articles/PMC10552211/ /pubmed/37798800 http://dx.doi.org/10.1186/s13075-023-03180-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Rodriguez-Martinez, Lorena
García-Moreno, Cristina
Perez-Pampin, Eva
Gómara, María J.
Sarmiento-Monroy, Juan C.
Lopez-Golán, Yolanda
Gómez-Puerta, José A.
Mera-Varela, Antonio
Conde, Carmen
Sanmartí, Raimon
Haro, Isabel
González, Antonio
Assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression
title Assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression
title_full Assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression
title_fullStr Assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression
title_full_unstemmed Assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression
title_short Assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression
title_sort assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552211/
https://www.ncbi.nlm.nih.gov/pubmed/37798800
http://dx.doi.org/10.1186/s13075-023-03180-x
work_keys_str_mv AT rodriguezmartinezlorena assessmentofantimalondialdehydeacetaldehydeantibodyfrequenciesinrheumatoidarthritiswithnewdatafromtwoindependentcohortsmetaanalysisandmetaregression
AT garciamorenocristina assessmentofantimalondialdehydeacetaldehydeantibodyfrequenciesinrheumatoidarthritiswithnewdatafromtwoindependentcohortsmetaanalysisandmetaregression
AT perezpampineva assessmentofantimalondialdehydeacetaldehydeantibodyfrequenciesinrheumatoidarthritiswithnewdatafromtwoindependentcohortsmetaanalysisandmetaregression
AT gomaramariaj assessmentofantimalondialdehydeacetaldehydeantibodyfrequenciesinrheumatoidarthritiswithnewdatafromtwoindependentcohortsmetaanalysisandmetaregression
AT sarmientomonroyjuanc assessmentofantimalondialdehydeacetaldehydeantibodyfrequenciesinrheumatoidarthritiswithnewdatafromtwoindependentcohortsmetaanalysisandmetaregression
AT lopezgolanyolanda assessmentofantimalondialdehydeacetaldehydeantibodyfrequenciesinrheumatoidarthritiswithnewdatafromtwoindependentcohortsmetaanalysisandmetaregression
AT gomezpuertajosea assessmentofantimalondialdehydeacetaldehydeantibodyfrequenciesinrheumatoidarthritiswithnewdatafromtwoindependentcohortsmetaanalysisandmetaregression
AT meravarelaantonio assessmentofantimalondialdehydeacetaldehydeantibodyfrequenciesinrheumatoidarthritiswithnewdatafromtwoindependentcohortsmetaanalysisandmetaregression
AT condecarmen assessmentofantimalondialdehydeacetaldehydeantibodyfrequenciesinrheumatoidarthritiswithnewdatafromtwoindependentcohortsmetaanalysisandmetaregression
AT sanmartiraimon assessmentofantimalondialdehydeacetaldehydeantibodyfrequenciesinrheumatoidarthritiswithnewdatafromtwoindependentcohortsmetaanalysisandmetaregression
AT haroisabel assessmentofantimalondialdehydeacetaldehydeantibodyfrequenciesinrheumatoidarthritiswithnewdatafromtwoindependentcohortsmetaanalysisandmetaregression
AT gonzalezantonio assessmentofantimalondialdehydeacetaldehydeantibodyfrequenciesinrheumatoidarthritiswithnewdatafromtwoindependentcohortsmetaanalysisandmetaregression